AR126595A1 - IMMUNE CELLS THAT EXPRESS CAR THAT SPECIFICALLY TARGET MESOTELIN AND USES THEREOF - Google Patents
IMMUNE CELLS THAT EXPRESS CAR THAT SPECIFICALLY TARGET MESOTELIN AND USES THEREOFInfo
- Publication number
- AR126595A1 AR126595A1 ARP220102009A ARP220102009A AR126595A1 AR 126595 A1 AR126595 A1 AR 126595A1 AR P220102009 A ARP220102009 A AR P220102009A AR P220102009 A ARP220102009 A AR P220102009A AR 126595 A1 AR126595 A1 AR 126595A1
- Authority
- AR
- Argentina
- Prior art keywords
- polynucleotide encoding
- mesothelin
- immune cells
- car
- antibody
- Prior art date
Links
- 210000002865 immune cell Anatomy 0.000 title abstract 5
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 6
- 102000003812 Interleukin-15 Human genes 0.000 abstract 5
- 108090000172 Interleukin-15 Proteins 0.000 abstract 5
- 102000040430 polynucleotide Human genes 0.000 abstract 5
- 108091033319 polynucleotide Proteins 0.000 abstract 5
- 239000002157 polynucleotide Substances 0.000 abstract 5
- 102100036842 C-C motif chemokine 19 Human genes 0.000 abstract 3
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 abstract 3
- 102000003735 Mesothelin Human genes 0.000 abstract 3
- 108090000015 Mesothelin Proteins 0.000 abstract 3
- 230000003834 intracellular effect Effects 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 101000576802 Homo sapiens Mesothelin Proteins 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Abstract
En el presente documento se describen células inmunitarias manipuladas que reconocen específicamente la mesotelina y expresan IL-15 y, opcionalmente, CCL19. También se describen en el presente documento moléculas de ácido nucleico aisladas que comprenden un polinucleótido que codifica un receptor de antígeno quimérico (CAR) que comprende un anticuerpo que reconoce específicamente la mesotelina y una región intracelular de 4-1BB; y un polinucleótido que codifica IL-15; y opcionalmente un polinucleótido que codifica CCL19, vectores, composiciones farmacéuticas que comprenden las moléculas de ácido nucleico y métodos para usar las células inmunitarias manipuladas. Reivindicación 1: Una molécula de ácido nucleico aislada caracterizada porque comprende un primer polinucleótido que codifica un receptor de antígeno quimérico (CAR) que comprende un anticuerpo que reconoce específicamente la mesotelina humana, y una región intracelular 4-1BB, y un segundo polinucleótido que codifica una interleucina 15 (IL-15). Reivindicación 39: Una célula inmunitaria caracterizada porque expresa: a) un receptor de antígeno quimérico (CAR) que comprende un anticuerpo que reconoce específicamente la mesotelina humana y una región intracelular de 4-1BB; y b) IL-15; y c) opcionalmente CCL19. Reivindicación 47: Un método para tratar un cáncer que expresa mesotelina caracterizado porque comprende administrar a un sujeto que lo necesite la célula inmunitaria de cualquiera de las reivindicaciones 35 - 44 o la composición farmacéutica de la reivindicación 46.Described herein are engineered immune cells that specifically recognize mesothelin and express IL-15 and, optionally, CCL19. Also described herein are isolated nucleic acid molecules comprising a polynucleotide encoding a chimeric antigen receptor (CAR) comprising an antibody that specifically recognizes mesothelin and an intracellular region of 4-1BB; and a polynucleotide encoding IL-15; and optionally a polynucleotide encoding CCL19, vectors, pharmaceutical compositions comprising the nucleic acid molecules and methods for using the engineered immune cells. Claim 1: An isolated nucleic acid molecule characterized in that it comprises a first polynucleotide encoding a chimeric antigen receptor (CAR) comprising an antibody that specifically recognizes human mesothelin, and an intracellular region 4-1BB, and a second polynucleotide encoding an interleukin 15 (IL-15). Claim 39: An immune cell characterized in that it expresses: a) a chimeric antigen receptor (CAR) comprising an antibody that specifically recognizes human mesothelin and an intracellular region of 4-1BB; and b) IL-15; and c) optionally CCL19. Claim 47: A method of treating a cancer that expresses mesothelin characterized in that it comprises administering to a subject in need thereof the immune cell of any of claims 35-44 or the pharmaceutical composition of claim 46.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063306862P | 2020-02-04 | 2020-02-04 | |
| US202163227115P | 2021-07-29 | 2021-07-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126595A1 true AR126595A1 (en) | 2023-10-25 |
Family
ID=88679243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102009A AR126595A1 (en) | 2020-02-04 | 2022-07-28 | IMMUNE CELLS THAT EXPRESS CAR THAT SPECIFICALLY TARGET MESOTELIN AND USES THEREOF |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR126595A1 (en) |
-
2022
- 2022-07-28 AR ARP220102009A patent/AR126595A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR104047A1 (en) | ANTI-CEACAM6 ANTIBODIES AND ITS USES | |
| AR110676A1 (en) | TREATMENT OF CANCER USING CHEMERIC ANTIGENS RECEPTORS | |
| AR102698A1 (en) | ANTIBODIES AGAINST CD73 AND ITS USES | |
| EA201791666A1 (en) | CD3 ANTIBODIES, CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES THAT SPECIFICALLY CONNECT WITH CD3 AND / OR CD123 | |
| EA201891670A1 (en) | PEPTIDES, PEPTIDE COMBINATIONS AND CELL BASED MEDICATIONS FOR USING URINARY BLADDER AND OTHER CANCER IMMUNOTHERAPY | |
| AR106365A1 (en) | BISPECIFIC MOLECULES OF ANTIGEN BINDING TO T-CELL ACTIVATORS | |
| MX2021005708A (en) | Anti-nkg2a antibodies and uses thereof. | |
| MX2020004741A (en) | Novel engineered t cell receptors and immune therapy using the same. | |
| PE20200384A1 (en) | METHOD OF MANUFACTURE OF BISPECIFIC ANTIBODIES, BISPECIFIC ANTIBODIES AND THERAPEUTIC USE OF SUCH ANTIBODIES | |
| EA201791925A1 (en) | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR THE APPLICATION IN IMMUNOTHERAPY OF SEVERAL TUMOR SPECIES | |
| EA202092735A1 (en) | ANTAGONIZING CD73 ANTIBODY | |
| CY1113089T1 (en) | Human Monoclonal Antibodies to Specific Protective Membrane Antigen (PSMA) | |
| AR096617A1 (en) | ANTI-TWEAKR ANTIBODIES AND THEIR USES | |
| BR112022001923A2 (en) | Antigen binding protein, isolated nucleic acid, recombinant host cell, pharmaceutical composition, antigen binding protein production method | |
| EA202091982A1 (en) | Chimeric antigenic receptor to the receptor of IL-13 ALPHA 2 (IL13R2) for tumor-specific T-cell immunotherapy | |
| PE20210517A1 (en) | ANTI-HLA-G ANTIBODIES AND THE USE OF THEM | |
| AR109683A1 (en) | ANTIBODIES AGAINST FACTOR XI AND ITS USES | |
| MX2021012003A (en) | Efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto. | |
| WO2020076977A3 (en) | Dll3 single domain antibodies and therapeutic compositions thereof | |
| BR112022001902A2 (en) | Bispecific antigen-binding protein, isolated nucleic acid, recombinant host cell, pharmaceutical composition and method for producing the bispecific antigen-binding protein | |
| PE20201255A1 (en) | CD123 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES SPECIFIC TO CD123 AND USES THEREOF | |
| MX2022010665A (en) | Antibodies binding il4r and uses thereof. | |
| MX2021011196A (en) | Anti-bcma chimeric antigen receptors. | |
| AR126595A1 (en) | IMMUNE CELLS THAT EXPRESS CAR THAT SPECIFICALLY TARGET MESOTELIN AND USES THEREOF | |
| ZA202304872B (en) | Anti-sclerostin constructs and uses thereof |